Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, comparative evaluation of the safety and efficacy of sirolimus versus cyclosporine when combined in a regimen containing basiliximab, mycophenolate mofetil, and corticosteroids in primary de novo allograft recipients

Next Previous
X
Search
Trial Profile

A randomized, open-label, comparative evaluation of the safety and efficacy of sirolimus versus cyclosporine when combined in a regimen containing basiliximab, mycophenolate mofetil, and corticosteroids in primary de novo allograft recipients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary) ; Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Wyeth

    • Most Recent Events

    • 03 Aug 2021 This trial is completed in Spain (Global End Date: 07 Jun 2006), according to European Clinical Trials Database record.
    • 27 Jul 2020 This trial is completed in UK (Global End Date: 07 Jun 2006), according to European Clinical Trials Database record.
    • 02 Sep 2009 Results presented at ESOT 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top